1. Home
  2. LBRDK vs TVTX Comparison

LBRDK vs TVTX Comparison

Compare LBRDK & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LBRDK

Liberty Broadband Corporation Class C

HOLD

Current Price

$36.77

Market Cap

4.8B

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$67.20

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDK
TVTX
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
5.3B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
LBRDK
TVTX
Price
$36.77
$67.20
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$40.62
AVG Volume (30 Days)
2.7M
1.6M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
29.91
92.89
EPS
4.55
N/A
Revenue
$22,256,000.00
N/A
Revenue This Year
N/A
$44.76
Revenue Next Year
$109.28
$35.51
P/E Ratio
$7.95
N/A
Revenue Growth
70.00
N/A
52 Week Low
$26.25
$17.28
52 Week High
$65.73
$67.34

Technical Indicators

Market Signals
Indicator
LBRDK
TVTX
Relative Strength Index (RSI) 56.88 64.24
Support Level $29.37 $53.76
Resistance Level $39.60 $66.24
Average True Range (ATR) 1.62 2.04
MACD -0.01 0.27
Stochastic Oscillator 71.46 79.41

Price Performance

Historical Comparison
LBRDK
TVTX

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: